Spain Pharmaceuticals and Healthcare Report Q1 2009

  • ID: 686916
  • February 2009
  • Region: Spain
  • 75 Pages
  • Business Monitor International
1 of 4


  • Almirall Prodesfarma
  • Dr Esteve
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

This Report on Spain’s Pharmaceuticals and Healthcare provides independent forecasts and competitive intelligence on Spain's pharmaceuticals and healthcare industry.

Spain’s drug market showed continued strong growth in 2008, with government backing for prescription drugs continuing to drive sales. The Q109 report sees forecasts extend through to 2013. Healthy levels of growth should prevail over this period, with average annual growth of 4.7%. Government support for patented drugs will lead to continued growth in sales; however, a growing need to use generics as a cost-saving measure will contain further rapid expansion. Regional autonomy in pharmaceutical policy means there are a range of cost-saving initiatives in Spain and the establishment of a unified scheme still appears unlikely in the short term. Meanwhile, following low levels of growth in the over-the-counter (OTC) market in recent years, sales should begin to increase slowly over the forecast period.

Spain places fifth in the Business Environment Rankings for Western Europe in Q109. Strong market dynamics are largely constrained by market risks, which include a sub-standard intellectual property READ MORE >

Note: Product cover images may vary from those shown
2 of 4


  • Almirall Prodesfarma
  • Dr Esteve
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

Executive Summary

Swot Analysis

- Spain: Pharmaceutical And Healthcare Industry SWOT
- Spain Political SWOT
- Spain Economic SWOT

Pharmaceutical Business Environment Ratings

- Table: Western Europe Pharmaceutical Business Environment Rankings
- Limits To Potential Returns
- Risks To Realisation Of Potential Returns

Spain - Market Summary

Regulatory Regime

- Intellectual Property Issues
- Pricing And Reimbursement Issues
- Table: Timeline - Spain's Pharmaceutical Pricing Reforms
- Price Cut On Older Drugs
- Reference Pricing System
- Industry Reaction
- Parallel Trade

Industry Developments

- Table: SNS Debt 2007

Industry Forecast Scenario

- Overall Market Forecast
- Table: Spain’s Drug Market Indicators, 2004-2013
- Key Growth Factors - Industry
- Table: Spain’s Health Expenditure Indicators, 2004-2013
- Key Growth Factors - Macroeconomic
- Table: Spain - Economic Activity
- Prescription Market Forecast
- Table: Spain - Prescription Drug Market Forecast (2004-2013)
- Patented Market Forecast
- Table: Spain’s Patented Drugs Market Indicators, 2004-2013
- Generics Market Forecast
- Table: Spain’s Generics Market Indicators, 2004-2013

OTC Market Forecast

- Table: Spain’s OTC Market Forecast Indicators (US$mn unless otherwise stated)
- Export/Import Forecast
- Table: Pharmaceutical Trade Indicators, 2004-2013 (US$mn)
- Medical Devices Forecast
- Table: Spain’s Medical Device Market, 2002-2012 (US$bn unless otherwise stated)
- Key Risks To BMI Forecasts

Competitive Landscape

- Manufacturers
- Foreign Sector
- Indigenous Sector
- Generics Sector
- Research/Biotechnology Sector Developments
- Table: Firms Active In Nanofarma Consortium
- Government Investment

Company Profiles

- Leading Multinational Manufacturers
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Sanofi-Aventis
- Merck & Co
- Indigenous Manufacturers
- Almirall Prodesfarma
- Dr Esteve

Country Snapshot: Spain Demographic Data

- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Manufacturing Wages, 2000-2012

BMI Forecast Modelling

- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources

Note: Product cover images may vary from those shown
3 of 4

- GlaxoSmithKline (GSK)

- Pfizer

- Novartis

- Sanofi-Aventis

- Merck & Co

- Almirall Prodesfarma

-Dr Esteve

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S